Premium
Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
Author(s) -
Zhang Xiaoping,
Imel Erik A.,
Ruppe Mary D.,
Weber Thomas J.,
Klausner Mark A.,
Ito Takahiro,
Vergeire Maria,
Humphrey Jeffrey,
Glorieux Francis H.,
Portale Anthony A.,
Insogna Karl,
Carpenter Thomas O.,
Peacock Munro
Publication year - 2016
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/jcph.570
Subject(s) - pharmacokinetics , pharmacodynamics , hypophosphatemia , medicine , pharmacology , monoclonal antibody , antibody , immunology
In X‐linked hypophosphatemia (XLH), serum fibroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D (1,25[OH] 2 D) concentration, with subsequent development of rickets or osteomalacia. KRN23 is a recombinant human IgG1 monoclonal antibody that binds to FGF23 and blocks its activity. Up to 4 doses of KRN23 were administered subcutaneously every 28 days to 28 adults with XLH. Mean ± standard deviation KRN23 doses administered were 0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg. The mean time to reach maximum serum KRN23 levels was 7.0 to 8.5 days. The mean KRN23 half‐life was 16.4 days. The mean area under the concentration–time curve (AUC n ) for each dosing interval increased proportionally with increases in KRN23 dose. The mean intersubject variability in AUC n ranged from 30% to 37%. The area under the effect concentration–time curve (AUEC n ) for change from baseline in TmP per glomerular filtration rate, serum Pi, 1,25(OH) 2 D, and bone markers for each dosing interval increased linearly with increases in KRN23 AUC n . Linear correlation between serum KRN23 concentrations and increase in serum Pi support KRN23 dose adjustments based on predose serum Pi concentration. © 2015 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology